153 0 Kommentare KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, CA.

“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista. “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines. This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice. We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected. It is our hope that if sebetralstat is approved for the on-demand treatment of HAE, it may be able to address this significant unmet need and help transform the management of the disease.”

In addition to the data on persisting non-medication health resource utilization among patients receiving long-term prophylaxis, the Company presented data on the global prevalence of HAE-nC1-INH the approach to the presumptive diagnosis, and the highly varied treatment approaches that represent another significant area of unmet need in that population.

The following presentations occurred at ACAAI 2023:

Anxiety Associated with On-Demand Treatment of HAE Attacks May Result in Suboptimal Attack Management: Michael Manning, Allergy, Asthma & Immunology Associates, Ltd., Internal Medicine, UA College of Medicine-Phoenix, Scottsdale, Arizona, United States (Poster Presentation)
Understanding Why Hereditary Angioedema Patients Often Do Not Carry Their On-Demand Treatment with Them: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
Treatment Patterns Among Individuals with Hereditary Angioedema in the United States: Raffi Tachdjian, University of California, Los Angeles, Los Angeles, CA, United States (Poster Presentation)
Refining Prevalence Estimates of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH): Markus Magerl, Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany (Poster Presentation)
Diagnosing Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real World ACARE Survey: Marc A. Riedl, Division of Rheumatology, Allergy and Immunology, University of California –San Diego, San Diego, California, United States (Poster Presentation)
Treatment of Hereditary Angioedema (HAE) with Normal C1-INH (HAE-nC1-INH) –A Real-World ACARE Survey: Marcus Maurer, Angioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany (Poster Presentation)